1551-P: Exploring Islet Autoantibody Positivity and β-Cell Function after Total Pancreatectomy with Islet Auto Transplantation

Le résumé fourni par la source

Introduction and Objective: Total pancreatectomy with islet auto transplantation (TPIAT) is a non-immune model of islet transplant. The presence of islet autoantibodies post TPIAT has been observed, but the impact on β cell function is unknown. We compared measures of β cell function between children who were islet autoantibody positive (IAP) and negative (IAN) for up to 2 years post TPIAT. Methods: Clinical data was collected from children who underwent TPIAT between 2015 and 2021. All patients were screened for islet autoantibodies and underwent Mixed Meal Tolerance Testing (MMTT) at 12 months and 18-24 months post TPIAT. IAP was defined as the detection of one or more of the following: Glutamic Acid Decarboxylase (GAD), Islet Antigen-2 (IA-2), or Zinc Transporter 8 (ZnT8). Insulin Antibody (IAA) was excluded due to the likelihood that detection was secondary to exogenous insulin exposure. At 12 months, 23 patients were identified: 7 IAP and 16 IAN. At 18-24 months, 20 patients were identified: 7 IAP and 13 IAN. Results: There were no differences in age at TPIAT, sex, or HbA1C levels between patients who were IAP or IAN. At 12 months post TPIAT, insulinogenic index, peak C peptide, C peptide secretion index and area under the curve C peptide were higher in the IAP group. BMI was significantly higher in the IAP group at 12 and 18-24 months. At 18-24 months, although not statistically significant, the median age was lower in the IAN group. Conclusion: The role of islet autoantibodies on β cell function post TPIAT remains unclear. IAP group is associated with increased insulin secretion post TPIAT. These data suggest that age and BMI influenced insulin secretion more than the presence of islet autoantibodies over this short post TPIAT duration. We suspect a longer exposure to islet antibodies is required to assess impact on β cell function. Disclosure O. Kothawala: None. L. Hornung: None. A.R. Lavik: None. S. Swauger: None. C.M.O. Lowe: None. M. Abu-El-Haija: None. S.E. Tellez: None. D.A. Elder: Research Support; Dexcom, Inc., Sanofi.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.